1-ethyl-3-(8-methyl-5-(pyridin-4-yl)isoquinolin-3-yl)urea | 1338255-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1-ethyl-3-(8-methyl-5-(pyridin-4-yl)isoquinolin-3-yl)urea
• 英文别名: 1-Ethyl-3-(8-methyl-5-pyridin-4-ylisoquinolin-3-yl)urea
• CAS: 1338255-30-3
• 化学式: C₁₈H₁₈N₄O
• 分子量: 306.367
• InChiKey: LCLDHRABJQNSRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-溴-8-甲基-异喹啉-3-基胺 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 122.0h， 生成 1-ethyl-3-(8-methyl-5-(pyridin-4-yl)isoquinolin-3-yl)urea
  参考文献：
  名称：

  Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents

  摘要：

  Our strategy to combat resistant bacteria consisted of targeting the GyrB/ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotics. Screening around the minimal ethyl urea binding motif led to the identification of isoquinoline ethyl urea 13 as a promising starting point for fragment evolution. The optimization was guided by structure-based design and focused on antibacterial activity in vitro and in vivo, culminating in the discovery of unprecedented substituents able to interact with conserved residues within the ATP-binding site. A detailed characterization of the lead compound highlighted the potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the identification of a suitable prodrug concept. Eventually, hERG K-channel block was identified as the main limitation of this chemical series, and efforts toward its minimization are reported.

  DOI：

  10.1021/acs.jmedchem.6b01834

文献信息

• [EN] ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOQUINOLÉIN-3-YLURÉE ANTIBACTÉRIENS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2011121555A1

  公开（公告）日：2011-10-06

  The invention relates to isoquinolin-3-ylurea derivatives of formula (I) wherein R1 represents (C1-C3)alkyl, (C1-C3)haloalkyl or cyclopropyl, R4 represents H and the substituents R2 and R3 and R5 have the meanings disclosed in the specification; and to the salts of such compounds. These compounds are useful for the prevention or the treatment of bacterial infections.

  这项发明涉及式（I）的异喹啉-3-基脲衍生物，其中R1代表（C1-C3）烷基，（C1-C3）卤代烷基或环丙基，R4代表H，取代基R2、R3和R5的含义在说明书中披露；以及这些化合物的盐。这些化合物可用于预防或治疗细菌感染。
• Isoquinolin-3-Ylurea Derivatives
  申请人：Bur Daniel

  公开号：US20130096119A1

  公开（公告）日：2013-04-18

  The invention relates to isoquinolin-3-ylurea derivatives of formula (I) wherein R 1 represents (C 1 -C 3 )alkyl, (C 1 -C 3 )haloalkyl or cyclopropyl, R 4 represents H and the substituents R 2 and R 3 and R 5 have the meanings disclosed in the specification; and to the salts of such compounds. These compounds are useful for the prevention or the treatment of bacterial infections.

  本发明涉及通式（I）的异喹啉-3-基脲衍生物，其中R1代表（C1-C3）烷基、（C1-C3）卤代烷基或环丙基，R4代表H，取代基R2、R3和R5具有说明书中披露的意义；以及涉及这些化合物的盐。这些化合物对于预防或治疗细菌感染有用。
• ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2552893A1

  公开（公告）日：2013-02-06
• Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents
  作者：Philippe Panchaud、Thierry Bruyère、Anne-Catherine Blumstein、Daniel Bur、Alain Chambovey、Eric A. Ertel、Markus Gude、Christian Hubschwerlen、Loïc Jacob、Thierry Kimmerlin、Thomas Pfeifer、Lars Prade、Peter Seiler、Daniel Ritz、Georg Rueedi

  DOI：10.1021/acs.jmedchem.6b01834

  日期：2017.5.11

  Our strategy to combat resistant bacteria consisted of targeting the GyrB/ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotics. Screening around the minimal ethyl urea binding motif led to the identification of isoquinoline ethyl urea 13 as a promising starting point for fragment evolution. The optimization was guided by structure-based design and focused on antibacterial activity in vitro and in vivo, culminating in the discovery of unprecedented substituents able to interact with conserved residues within the ATP-binding site. A detailed characterization of the lead compound highlighted the potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the identification of a suitable prodrug concept. Eventually, hERG K-channel block was identified as the main limitation of this chemical series, and efforts toward its minimization are reported.